Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oligonucleotides, Antisense | 19 | 2025 | 144 | 6.890 |
Why?
|
| Oligonucleotides | 21 | 2025 | 221 | 4.550 |
Why?
|
| RNA, Small Interfering | 14 | 2024 | 921 | 2.930 |
Why?
|
| Gene Editing | 11 | 2025 | 322 | 2.360 |
Why?
|
| Gene Silencing | 11 | 2024 | 400 | 2.190 |
Why?
|
| RNA | 10 | 2024 | 423 | 1.510 |
Why?
|
| Nucleic Acids | 2 | 2022 | 60 | 1.280 |
Why?
|
| RNA Interference | 8 | 2024 | 618 | 1.090 |
Why?
|
| CRISPR-Cas Systems | 6 | 2025 | 361 | 1.040 |
Why?
|
| RNA, Double-Stranded | 6 | 2020 | 112 | 1.020 |
Why?
|
| Brain Neoplasms | 3 | 2024 | 310 | 0.980 |
Why?
|
| DNA | 11 | 2025 | 837 | 0.970 |
Why?
|
| Glioblastoma | 2 | 2024 | 158 | 0.960 |
Why?
|
| Fibroblasts | 4 | 2022 | 394 | 0.870 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 190 | 0.870 |
Why?
|
| Friedreich Ataxia | 2 | 2022 | 7 | 0.830 |
Why?
|
| Genetic Therapy | 5 | 2025 | 791 | 0.800 |
Why?
|
| RNA, Long Noncoding | 3 | 2024 | 170 | 0.780 |
Why?
|
| Splints | 1 | 2021 | 6 | 0.740 |
Why?
|
| Arabinonucleotides | 3 | 2010 | 4 | 0.720 |
Why?
|
| Gene Expression Regulation | 6 | 2022 | 1617 | 0.700 |
Why?
|
| RNA, Messenger | 5 | 2022 | 1537 | 0.700 |
Why?
|
| Endothelial Cells | 1 | 2022 | 187 | 0.690 |
Why?
|
| Mice | 16 | 2024 | 10846 | 0.680 |
Why?
|
| Phenotype | 1 | 2024 | 1207 | 0.680 |
Why?
|
| Animals | 25 | 2025 | 20666 | 0.660 |
Why?
|
| Proprotein Convertase 9 | 1 | 2020 | 13 | 0.640 |
Why?
|
| Acetylgalactosamine | 2 | 2024 | 10 | 0.640 |
Why?
|
| Peptide Nucleic Acids | 2 | 2018 | 16 | 0.620 |
Why?
|
| Drug Delivery Systems | 4 | 2022 | 325 | 0.600 |
Why?
|
| Lung | 3 | 2023 | 956 | 0.600 |
Why?
|
| Triazoles | 2 | 2018 | 56 | 0.570 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 107 | 0.540 |
Why?
|
| RNAi Therapeutics | 1 | 2017 | 11 | 0.530 |
Why?
|
| Humans | 39 | 2025 | 63512 | 0.520 |
Why?
|
| Monosaccharides | 2 | 2007 | 8 | 0.510 |
Why?
|
| Uridine | 2 | 2007 | 22 | 0.510 |
Why?
|
| Cells, Cultured | 5 | 2022 | 2157 | 0.440 |
Why?
|
| Antiviral Agents | 2 | 2023 | 324 | 0.430 |
Why?
|
| Phosphorothioate Oligonucleotides | 2 | 2024 | 10 | 0.410 |
Why?
|
| Organophosphorus Compounds | 3 | 2023 | 31 | 0.410 |
Why?
|
| Cytidine Deaminase | 2 | 2025 | 86 | 0.400 |
Why?
|
| Central Nervous System | 2 | 2024 | 197 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 837 | 0.370 |
Why?
|
| Iron-Binding Proteins | 2 | 2022 | 11 | 0.340 |
Why?
|
| Zebrafish | 2 | 2025 | 347 | 0.330 |
Why?
|
| Thermodynamics | 2 | 2010 | 196 | 0.330 |
Why?
|
| RNA, Antisense | 1 | 2010 | 51 | 0.320 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 1471 | 0.320 |
Why?
|
| Liver | 4 | 2024 | 855 | 0.310 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 190 | 0.310 |
Why?
|
| Organoselenium Compounds | 1 | 2008 | 4 | 0.290 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2025 | 504 | 0.290 |
Why?
|
| Oligoribonucleotides | 1 | 2008 | 15 | 0.290 |
Why?
|
| Aptamers, Nucleotide | 2 | 2021 | 22 | 0.290 |
Why?
|
| Genome, Human | 2 | 2021 | 237 | 0.280 |
Why?
|
| Enzyme Inhibitors | 2 | 2025 | 373 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 676 | 0.270 |
Why?
|
| Precision Medicine | 2 | 2025 | 120 | 0.260 |
Why?
|
| Nanoparticles | 3 | 2021 | 513 | 0.240 |
Why?
|
| Base Sequence | 7 | 2022 | 1331 | 0.240 |
Why?
|
| Genome | 2 | 2025 | 276 | 0.230 |
Why?
|
| Gene Knock-In Techniques | 1 | 2025 | 43 | 0.230 |
Why?
|
| Models, Molecular | 4 | 2021 | 1150 | 0.230 |
Why?
|
| Rare Diseases | 1 | 2025 | 42 | 0.230 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2025 | 53 | 0.220 |
Why?
|
| Trinucleotide Repeat Expansion | 3 | 2023 | 32 | 0.220 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2024 | 20 | 0.220 |
Why?
|
| Deoxyribonucleotides | 1 | 2024 | 13 | 0.220 |
Why?
|
| Molecular Conformation | 3 | 2017 | 133 | 0.220 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2024 | 39 | 0.220 |
Why?
|
| Ribonuclease H | 2 | 2018 | 18 | 0.220 |
Why?
|
| DNA, Single-Stranded | 2 | 2022 | 107 | 0.210 |
Why?
|
| C9orf72 Protein | 2 | 2022 | 114 | 0.210 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2024 | 107 | 0.210 |
Why?
|
| Information Dissemination | 1 | 2025 | 116 | 0.210 |
Why?
|
| RNA Splicing | 2 | 2022 | 162 | 0.210 |
Why?
|
| Mice, Nude | 1 | 2024 | 277 | 0.210 |
Why?
|
| Adenine | 1 | 2024 | 50 | 0.210 |
Why?
|
| Technology | 1 | 2023 | 53 | 0.210 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2023 | 15 | 0.210 |
Why?
|
| Drug Design | 2 | 2017 | 136 | 0.200 |
Why?
|
| Endonucleases | 1 | 2023 | 84 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 203 | 0.200 |
Why?
|
| Fragile X Syndrome | 1 | 2023 | 27 | 0.200 |
Why?
|
| DNA Repair | 2 | 2021 | 248 | 0.200 |
Why?
|
| Trachea | 1 | 2022 | 85 | 0.190 |
Why?
|
| Motor Activity | 1 | 2024 | 346 | 0.180 |
Why?
|
| Trypsin | 1 | 2021 | 39 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 207 | 0.170 |
Why?
|
| Endoribonucleases | 1 | 2021 | 56 | 0.170 |
Why?
|
| Cells | 1 | 2021 | 32 | 0.170 |
Why?
|
| Chromatids | 1 | 2020 | 14 | 0.170 |
Why?
|
| Chromosome Segregation | 1 | 2020 | 40 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 117 | 0.170 |
Why?
|
| Frontotemporal Dementia | 1 | 2022 | 149 | 0.160 |
Why?
|
| Germany | 1 | 2019 | 54 | 0.160 |
Why?
|
| Circular Dichroism | 3 | 2010 | 108 | 0.160 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1354 | 0.150 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2018 | 3 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 2187 | 0.150 |
Why?
|
| Water | 2 | 2010 | 309 | 0.150 |
Why?
|
| Transcription Factor 4 | 1 | 2018 | 2 | 0.140 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2018 | 5 | 0.140 |
Why?
|
| Macromolecular Substances | 1 | 2018 | 160 | 0.140 |
Why?
|
| Chromatin | 2 | 2020 | 608 | 0.140 |
Why?
|
| Mutation | 2 | 2024 | 2615 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 178 | 0.130 |
Why?
|
| Hepatocytes | 1 | 2018 | 218 | 0.130 |
Why?
|
| Nucleosides | 2 | 2007 | 11 | 0.130 |
Why?
|
| Escherichia coli | 1 | 2021 | 707 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 1186 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 130 | 0.130 |
Why?
|
| Nucleic Acid Conformation | 3 | 2020 | 239 | 0.130 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 69 | 0.120 |
Why?
|
| ADAM Proteins | 1 | 2016 | 32 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 297 | 0.120 |
Why?
|
| Cell Membrane | 1 | 2018 | 496 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 790 | 0.110 |
Why?
|
| Molecular Imprinting | 1 | 2014 | 5 | 0.110 |
Why?
|
| Binding Sites | 1 | 2017 | 906 | 0.110 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 677 | 0.110 |
Why?
|
| Alleles | 2 | 2018 | 448 | 0.110 |
Why?
|
| Hepacivirus | 1 | 2015 | 141 | 0.110 |
Why?
|
| RNA Polymerase II | 2 | 2014 | 84 | 0.110 |
Why?
|
| Nucleic Acid Denaturation | 2 | 2010 | 7 | 0.100 |
Why?
|
| Models, Genetic | 1 | 2014 | 260 | 0.100 |
Why?
|
| Cations | 2 | 2011 | 64 | 0.100 |
Why?
|
| Catalytic Domain | 2 | 2025 | 199 | 0.100 |
Why?
|
| Hydrogen Bonding | 2 | 2010 | 129 | 0.100 |
Why?
|
| Male | 5 | 2025 | 29927 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2024 | 687 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2011 | 385 | 0.090 |
Why?
|
| Spermine | 1 | 2011 | 3 | 0.090 |
Why?
|
| Polymers | 1 | 2014 | 325 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2011 | 127 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2018 | 1513 | 0.080 |
Why?
|
| Fluorine | 1 | 2010 | 9 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 110 | 0.080 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 113 | 0.080 |
Why?
|
| Crotalus | 1 | 2009 | 1 | 0.080 |
Why?
|
| 2',3'-Cyclic-Nucleotide Phosphodiesterases | 1 | 2009 | 3 | 0.080 |
Why?
|
| Viper Venoms | 1 | 2009 | 2 | 0.080 |
Why?
|
| Alkalies | 1 | 2009 | 4 | 0.080 |
Why?
|
| RNA, Untranslated | 1 | 2010 | 103 | 0.080 |
Why?
|
| Acids | 1 | 2009 | 14 | 0.080 |
Why?
|
| Stereoisomerism | 1 | 2009 | 69 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 320 | 0.080 |
Why?
|
| Hydrolysis | 1 | 2009 | 144 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2011 | 346 | 0.070 |
Why?
|
| Catalysis | 1 | 2009 | 161 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 455 | 0.070 |
Why?
|
| Biophysical Phenomena | 1 | 2008 | 23 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 213 | 0.070 |
Why?
|
| Research Design | 1 | 2011 | 574 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 98 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 424 | 0.070 |
Why?
|
| Biophysics | 1 | 2008 | 42 | 0.070 |
Why?
|
| Nucleotides | 1 | 2008 | 49 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2021 | 622 | 0.070 |
Why?
|
| Introns | 2 | 2018 | 111 | 0.070 |
Why?
|
| Carbohydrate Conformation | 1 | 2007 | 15 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 778 | 0.060 |
Why?
|
| Glycosylation | 1 | 2006 | 138 | 0.060 |
Why?
|
| Recombinational DNA Repair | 1 | 2025 | 25 | 0.060 |
Why?
|
| Injections, Spinal | 1 | 2025 | 46 | 0.060 |
Why?
|
| Cytidine | 1 | 2025 | 15 | 0.060 |
Why?
|
| APOBEC Deaminases | 1 | 2025 | 10 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 294 | 0.060 |
Why?
|
| Moloney murine leukemia virus | 1 | 2024 | 17 | 0.060 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2025 | 88 | 0.060 |
Why?
|
| Antagomirs | 1 | 2024 | 5 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2024 | 109 | 0.050 |
Why?
|
| Templates, Genetic | 1 | 2023 | 22 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 292 | 0.050 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2022 | 21 | 0.050 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2023 | 38 | 0.050 |
Why?
|
| Neurons | 2 | 2021 | 923 | 0.050 |
Why?
|
| Biotinylation | 1 | 2022 | 36 | 0.050 |
Why?
|
| Dipeptides | 1 | 2022 | 68 | 0.050 |
Why?
|
| Exons | 1 | 2022 | 199 | 0.050 |
Why?
|
| Biotin | 1 | 2022 | 52 | 0.050 |
Why?
|
| K562 Cells | 1 | 2021 | 58 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 525 | 0.050 |
Why?
|
| Cell-Free System | 1 | 2021 | 31 | 0.040 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2021 | 21 | 0.040 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 34 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 385 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2022 | 257 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 313 | 0.040 |
Why?
|
| Serum Albumin, Bovine | 1 | 2021 | 35 | 0.040 |
Why?
|
| Muramidase | 1 | 2021 | 46 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 2022 | 114 | 0.040 |
Why?
|
| G-Quadruplexes | 1 | 2020 | 6 | 0.040 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2020 | 26 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 90 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2040 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 119 | 0.040 |
Why?
|
| Mitosis | 1 | 2020 | 218 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2021 | 271 | 0.040 |
Why?
|
| DNA Replication | 1 | 2020 | 236 | 0.040 |
Why?
|
| Particle Size | 1 | 2020 | 407 | 0.040 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2018 | 2 | 0.040 |
Why?
|
| Endothelium, Corneal | 1 | 2018 | 5 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1277 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 78 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2018 | 116 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 457 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 100 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 265 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3396 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1409 | 0.030 |
Why?
|
| Proteins | 1 | 2022 | 750 | 0.030 |
Why?
|
| Aged | 2 | 2025 | 14469 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2020 | 564 | 0.030 |
Why?
|
| Adult | 2 | 2025 | 16837 | 0.030 |
Why?
|
| Female | 3 | 2025 | 32912 | 0.030 |
Why?
|
| Middle Aged | 2 | 2025 | 17641 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 508 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2025 | 5699 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 719 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 202 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2011 | 39 | 0.020 |
Why?
|
| Ataxin-3 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 93 | 0.020 |
Why?
|
| Transition Temperature | 1 | 2010 | 6 | 0.020 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2010 | 29 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2010 | 18 | 0.020 |
Why?
|
| Interferons | 1 | 2010 | 73 | 0.020 |
Why?
|
| RNA Stability | 1 | 2010 | 102 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2010 | 220 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 321 | 0.020 |
Why?
|
| Child | 1 | 2018 | 4528 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 5471 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7855 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1991 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 396 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 429 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 574 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 6248 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1180 | 0.020 |
Why?
|